Who is sponsoring NCT03862196?

NCT03862196 is sponsored by NGO Via Libre.

What drugs are being tested in NCT03862196?

Interventions in NCT03862196: Tailored text messages to improve retention in HIV care.

Is NCT03862196 still recruiting?

NCT03862196 is currently status unknown. Last updated 5 March 2019.

Last reviewed 2019-03-05 · How we verify

NCT03862196

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of SMS to Improve Early Retention in HIV Care for PLWH in Lima

Status unknown NA Last updated 5 March 2019

What this trial tests

NA trial testing Tailored text messages to improve retention in HIV care in HIV in 144 participants. Status unknown.

Timeline

21 December 2018

Primary endpoint
11 April 2019

7 August 2019

Quick facts

Lead sponsor	NGO Via Libre
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	144
Start date	21 December 2018
Primary completion	11 April 2019
Estimated completion	7 August 2019
Sites	1 location across Peru

Drugs / interventions tested

Tailored text messages to improve retention in HIV care

Conditions studied

HIV — all drugs for HIV →

Sponsor

NGO Via Libre

Who can join

18 and older, male only, with HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized controlled study that will evaluate the effect of a text message-based strategy to improve retention in HIV care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03862196 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NGO Via Libre
Last refreshed: 5 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03862196.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing